Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression | To Be Presented as Late-Breaking Science at the THT 2025 Conferencenews2025-02-12T16:14:04+00:00February 12th, 2025|Medical Device News Magazine|
Glooko and Innovation Zed Partner to Revolutionize Injectable Therapy Management with Digital Companion Appsnews2025-02-06T11:14:40+00:00February 6th, 2025|Medical Device News Magazine|
Fore Genomics Partners with Inocras to Launch Pediatric Genetic Health Screening and Newborn Sequencingnews2025-02-03T16:38:12+00:00February 3rd, 2025|Medical Device News Magazine|
ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovationnews2025-01-17T15:14:28+00:00January 17th, 2025|Medical Device News Magazine|
Revvity and Element Biosciences Collaboration | To Advance Sequencing-based IVD Neonatal Testingnews2025-01-13T15:17:21+00:00January 13th, 2025|Medical Device News Magazine|
Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophynews2025-01-02T17:18:42+00:00January 2nd, 2025|Medical Device News Magazine|
PharmaEssentia Reaffirms its Commitment to Robust and Reliable Access to Interferon Therapies Amid Global Supply Challengesnews2025-01-02T17:11:43+00:00January 2nd, 2025|Medical Device News Magazine|
YolTech Therapeutics Granted FDA Orphan Drug and Rare Pediatric Disease Designations for YOLT-203 to Treat Primary Hyperoxaluria Type 1news2024-12-27T15:39:38+00:00December 27th, 2024|Medical Device News Magazine|
Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the “AD-DMT Registry” in Japannews2024-11-26T09:12:12+00:00November 26th, 2024|Medical Device News Magazine|
Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial (“INVINCIBLE-3 Study”) in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)news2024-11-18T16:33:33+00:00November 18th, 2024|Medical Device News Magazine|